Premium
O4‐02‐03: Locus ceruleus volume changes are a promising biomarker for detecting Alzheimer's disease progression in pre‐symptomatic stages
Author(s) -
Theofilas Panos,
Dunlop Sara,
Ehrenberg Alexander J.,
Alho Ana T.,
Nguy Austin,
Paraizo Leite Renata Elaine,
Rodriguez Roberta Diehl,
Mejia Maria B.,
Suemoto Claudia K.,
Farfel Jose M.,
Eloah de Lucena Ferretti-Rebustini Renata,
Polichiso Livia,
Prata Thamiris V.G.,
Nascimento Camila F.,
Seeley William W.,
Nitrini Ricardo,
Pasquallucci Carlos Augusto,
Jacob-Filho Wilson,
Rueb Udo,
Neuhaus John,
Heinsen Helmut,
Grinberg Lea T.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.353
Subject(s) - locus ceruleus , brainstem , locus coeruleus , biomarker , pons , neuroscience , pathology , alzheimer's disease , human brain , entorhinal cortex , neuromelanin , disease , medicine , psychology , central nervous system , biology , parkinson's disease , substantia nigra , hippocampus , biochemistry
with non-fluent variant primary progressive aphasia showed asymmetric binding in the left inferior frontal and parietal cortex (Figure 2). Tracer binding was unexpectedly seen in all 3 patients with FTD due to presumed tau-negative, TDP43-posistive inclusions, particularly in degenerating white matter (Figure 3). 1/2 patients at risk for CTE showed focal AV1451 binding in the left anterior temporal lobe (Figure 4). Conclusions:AV1451 uptake largely conformed to the expected distribution of pathology in non-AD tauopathies, though subcortical signal overlapped with binding in NC. Unexpected AV1451 uptake was also found in patients with presumed tau-negative, FTD-TDP pathology. PET-to-autopsy correlation studies are needed to better characterize these findings.